Latest news with #CNBCDisruptor50
CNBC
2 days ago
- Business
- CNBC
Oura, Maven Clinic team up to bring biometric data into clinical care
Women's and family health platform Maven Clinic is partnering with smart ring maker Oura, a step forward in the integration of the increasing amount of data being collected by wearable devices and clinical care. As part of the partnership, eligible Maven members will be able to sync the data that their Oura Ring collects with the Maven platform, allowing members of the Maven care team to comb over the Oura-collected data like sleep, stress and activity to provide enhanced health guidance. Maven Clinic, a three-time CNBC Disruptor 50 company, is the largest virtual clinic for women's and family health with more than 2,000 employers and health plans using its platform. The company, which raised a $125 million funding round valuing it at $1.7 billion in October 2024, offers programs that range from fertility and family building to maternity and newborn care to menopause and midlife health. Kate Ryder, CEO and founder of Maven Clinic, said that we're in a "reinvigorated era of consumer health," a period that is being defined by the amount of data being collected via wearables and the desire of people to use those diagnostics to seek treatment and advice. Ryder said that a recent survey of Maven Clinic members found that nearly three out of four members are tracking their health regularly with some sort of device, and consumers are asking, "How do I take my health into my own hands with all these tools and areas of wellness at my fingertips to try to live a healthier life?" That shift prompted Maven's new partnership with Oura, also a three-time Disruptor 50 company, which was ranked No. 23 on the 2025 CNBC Disruptor 50 list and has been on its own path of wellness and preventive health via its eponymous Ring in recent years. While Oura's initial focus centered on tracking sleep and recovery metrics, its scope has widened significantly in recent years to broader healthcare and personal health issues. As Oura CEO Tom Hale said in a recent CNBC interview, "the vision for the future of Oura has to do with the doctor in your pocket." That includes a wide variety of metrics, features and health indicators tracked by the Oura Ring and parsed by the company's AI and analytics to offer wearers' health insights, including a variety of female-focused features around menstrual, period and pregnancy cycles. "One of our key theses is that women have been overlooked in science, and in health understudied and overlooked, but we believe that they expect the same level of personalization, transparency and immediacy from their healthcare," said Oura chief commercial officer Dorothy Kilroy. "This is what they want, and traditional healthcare hasn't really kept up with that for women and their families." Kilroy said that the partnership between the two companies aims to deliver that, offering "smart, connected personalized care that'll fit into their lives and not the other way around, which is kind of what the old healthcare systems have provided." The ultimate goal is to improve health outcomes through the utilization of the data collected by the Oura Ring, allowing for more personalized recommendations, the ability to catch issues sooner and be more proactive, and layering in expert medical care at critical points. "Tracking is the first step, but really it's not just about surfacing health data," Ryder said, noting that Maven Clinic is the first virtual care platform to turn Oura's health signals into expert care. "We really want to act on it to actually drive better outcomes." One example of how the data could be utilized would be in the case of a pregnant Maven member diagnosed with gestational diabetes. That person could work with a Maven nutritionist or support coach to help regulate their glucose levels, while using Oura's physical activity tracking and meals and glucose features to monitor their progress. Oura is increasingly working with a variety of partners in the healthcare sector to use the biometric data collected by its Rings, Kilroy said, allowing it to be "paired with clinical care and creating that kind of seamless experience where the members can both understand what's going on in their body but they can actually use that to get expert care all in one place." Ryder said that she sees the convergence of this sort of biometric tracking and the clinical side as leading towards much more effective preventative care, leading to "much better outcomes," especially among high-risk patients where this sort of reporting and engagement can result in significant improvements in health. Maven Clinic will start to integrate the Oura data into its platform starting later this summer, with a goal of having it reach all members who want to opt in by the winter. Maven members will also receive exclusive pricing on the purchase of an Oura Ring. "We have to shift our healthcare system into prevention and invest more in wellness and wellbeing," Ryder said. "There's a lot of exciting stuff that this partnership can do to take the step forward, be innovative and show the outcomes on the back end."
CNBC
3 days ago
- Business
- CNBC
Fintech Ramp's valuation hits $16 billion in deal led by Peter Thiel's Founders Fund
Ramp, which offers a financial operations platforms to corporate clients, has raised its valuation to $16 billion in a new fundraising led by long-time investor Founders Fund, Peter Thiel's venture firm. The $200 million round is the fifth that Founders' has led for Ramp and raised its valuation by $3 billion. It last raised money at a $13 billion valuation in March. Founded in 2019, Ramp offers services that cover corporate cards, procurement, bookkeeping, travel booking, and vendor management, and says it handles tens of billions in purchases annually across 40,000 companies. Ramp ranked No. 6 on the 2025 CNBC Disruptor 50 list. Its list of clients includes CBRE, Shopify and two fellow 2025 CNBC Disruptor 50 companies, Anduril and Notion (Founders Fund is also an investor in Anduril). Ramp has been increasing its offerings for enterprise companies. In January, it launched Ramp Treasury, which allows companies to earn 2.5% on idle operating cash. It also acquired Venue, an AI-powered procurement software startup, and used it to roll out new vendor payment tools. Last June, it debuted Ramp Travel, partnering with Priceline for booking and managing expenses for corporate travel, moving into the market of fellow Disruptor Navan. The company says it has shipped 270 features this year, with a focus on increased automation of financial operations and use of AI, and still serves only 1.5% of the addressable U.S. market. Ramp co-founder and CEO Eric Glyman wrote in a blog post about the fundraising that he is guided by his favorite companies' missions: "Increase the GDP of the internet (ten-time Disruptor Stripe); Make humanity a multiplanetary species (SpaceX); Be Earth's most customer-obsessed company (Amazon)." "Ours can fit on a Post-it too," he wrote. "Save your company time and money (without you noticing)." "Let the robots chase receipts and close your books, so you can use your brain and build things," he added. Additional investors in the round included Thrive Capital, D1 Capital Partners, General Catalyst, GIC, ICONIQ Growth, Khosla Ventures, Sands Capital, 8VC, Lux Capital, Stripes, 137 Ventures, Avenir Growth, and Definition Capital.
NBC News
7 days ago
- Business
- NBC News
Anne Wojcicki to buy back 23andMe and its data for $305 million
Anne Wojcicki, the co-founder and former CEO of 23andMe, has regained control over the embattled genetic testing company after her new nonprofit, TTAM Research Institute, outbid Regeneron Pharmaceuticals, the company announced Friday. TTAM will acquire substantially all of 23andMe's assets for $305 million, including its Personal Genome Service and Research Services business lines as well as telehealth subsidiary Lemonaid Health. It's a big win for Wojcicki, who stepped down from her role as CEO when 23andMe filed for Chapter 11 bankruptcy protection in March. Last month, Regeneron announced it would purchase most of 23andMe's assets for $256 million after it came out on top during a bankruptcy auction. But Wojcicki submitted a separate $305 million bid through TTAM and pushed to reopen the auction. TTAM is an acronym for the first letters of 23andMe, according to The Wall Street Journal. 'I am thrilled that TTAM Research Institute will be able to continue the mission of 23andMe to help people access, understand and benefit from the human genome,' Wojcicki said in a statement. 23andMe gained popularity because of its at-home DNA testing kits that gave customers insight into their family histories and genetic profiles. The five-time CNBC Disruptor 50 company went public in 2021 via a merger with a special purpose acquisition company. At its peak, 23andMe was valued at around $6 billion. The company struggled to generate recurring revenue and stand up viable research and therapeutics businesses after going public, and it has been plagued by privacy concerns since hackers accessed the information of nearly seven million customers in 2023.
CNBC
7 days ago
- Business
- CNBC
Anne Wojcicki to buy back 23andMe and its data for $305 million
Anne Wojcicki, the co-founder and former CEO of 23andMe, has regained control over the embattled genetic testing company after her new nonprofit, TTAM Research Institute, out bid Regeneron Pharmaceuticals, the company announced on Friday. TTAM will acquire substantially all of 23andMe's assets for $305 million, including its Personal Genome Service and Research Services business lines as well as telehealth subsidiary Lemonaid Health. It's a big win for Wojcicki, who stepped down from her role as CEO when 23andMe filed for for Chapter 11 bankruptcy protection in March. Last month, Regeneron announced that it would purchase most of 23andMe's assets for $256 million after it came out on top during a bankruptcy auction. But Wojcicki submitted a separate $305 million bid through TTAM and pushed to reopen the auction. TTAM is an acronym for the first letters of 23andMe, according to the Wall Street Journal. "I am thrilled that TTAM Research Institute will be able to continue the mission of 23andMe to help people access, understand and benefit from the human genome," Wojcicki said in a statement. 23andMe gained popularity because of its at-home DNA testing kits that gave customers insight into their family histories and genetic profiles. The five-time CNBC Disruptor 50 company went public in 2021 via a merger with a special purpose acquisition company. At its peak, 23andMe was valued at around $6 billion. The company struggled to generate recurring revenue and stand up viable research and therapeutics businesses after going public, and it's been plagued by privacy concerns since hackers accessed the information of nearly 7 million customers in 2023. TTAM's acquisition is still subject to approval by the U.S. Bankruptcy Court for the Eastern District of Missouri.
CNBC
12-06-2025
- Business
- CNBC
Chime Financial opens at $43 per share, compared to IPO price of $27
CNBC's Leslie Picker joins 'The Exchange' to discuss Chime making its public debut opening at $43 per share on the Nasdaq. The online banking services provider is a five-time CNBC Disruptor 50 company.
